Sorry, you need to enable JavaScript to visit this website.

REVATIO® (sildenafil citrate) Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use REVATIO safely and effectively. See full prescribing information for REVATIO.

REVATIO (sildenafil) tablets, for oral use
REVATIO (sildenafil) for oral suspension
REVATIO (sildenafil) injection, for intravenous use
Initial U.S. Approval: 1998

RECENT MAJOR CHANGES

Warnings and Precautions, Visual Loss (5.5) 7/2017

INDICATIONS AND USAGE

REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with NYHA Functional Class II–III symptoms. Etiologies were idiopathic (71%) or associated with connective tissue disease (25%). (1)

Limitation of Use: Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity. (1, 14)

DOSAGE AND ADMINISTRATION

  • Tablet and oral suspension: 5 mg or 20 mg three times a day, 4–6 hours apart (2.1)
  • Injection: 2.5 mg or 10 mg three times a day administered as an intravenous bolus injection (2.2)

DOSAGE FORMS AND STRENGTHS

  • Tablets: 20 mg (3)
  • Injection: 10 mg /12.5 mL in a single use vial (3)
  • For Oral Suspension: 10 mg/mL (when reconstituted) (3)

CONTRAINDICATIONS

  • Use with organic nitrates or riociguat (4)
  • History of hypersensitivity reaction to sildenafil or any component of the tablet, injection, or oral suspension (4)

WARNINGS AND PRECAUTIONS

  • Increased mortality with increasing doses in pediatric patients. Not recommended for use in pediatric patients. (5.1)
  • Vasodilation effects may be more common in patients with hypotension or on antihypertensive therapy. (5.2)
  • Use in pulmonary veno-occlusive disease may cause pulmonary edema and is not recommended. (5.3)
  • Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs. (5.5, 5.6)
  • Pulmonary hypertension secondary to sickle cell disease: REVATIO may cause serious vaso-occlusive crises. (5.9)

ADVERSE REACTIONS

Most common adverse reactions greater than or equal to 3% and more frequent than placebo were epistaxis, headache, dyspepsia, flushing, insomnia, erythema, dyspnea, and rhinitis. (6.1, 6.2)


To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Concomitant alpha-blockers or amlodipine: Note additive blood pressure lowering effects. (7)
  • Use with ritonavir and other potent CYP3A inhibitors: Not recommended. (7, 12.3)
  • Concomitant PDE-5 inhibitors: Avoid use with Viagra or other PDE-5 inhibitors. (5.7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 1/2019

What's New

No Current Announcements.

Therapeutic Area

Contact Pfizer Medical

Report an Adverse Event
1-800-438-1985

Search

Please enter your search term(s) for REVATIO®

Contact Pfizer

Need to report an Adverse Event, Side Effect or Product Quality Concern?

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch

Have a Medical Question on a Pfizer Prescription Medicine?
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Have a Question on a Pfizer Over-the-Counter Product?
For Pfizer Consumer Healthcare non-prescription or over-the-counter products such as Advil, Centrum, Nexium or Thermacare, call (800) 322-3129
Have a Question about Pfizer Clinical Trials?
If you are looking for information about Pfizer studies currently recruiting new patients in your area, you can begin your search on our website. For questions about a Pfizer Clinical Trial, call (800) 718-1021 or email [email protected]
Need Information on Pfizer’s Patient Assistance Programs?

Pfizer RxPathways® connects eligible patients, regardless of their insurance status, to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. For more information, please call (844) 989-7284 or visit www.PfizerRxPathways.com.

Eligible patients can register for valuable savings offers for nearly 40 brand name medications. Visit www.MyPfizerBrands.com for more information.